Sign in to view content

Safety of Intravitreal Pegcetacoplan in Geographic Atrophy: Results from the Phase 3 DERBY and OAKS Trials

David S. Boyer, MD

Video
Published 2021

Related

Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes
Carl D. Regillo, MD
Annual Meeting Talks
2022
Safety and Efficacy of Switching to Biosimilar Ranibizumab in Eyes Initially Treated With Reference Ranibizumab for nAMD, DME, or RVO
Nikhil K Bommakanti, MD
Annual Meeting Talks
2024
Quality of Life and Retinal Disease During the COVID-19 Pandemic
Peter Y Zhao, MD
Annual Meeting Talks
2021

Category: AMD-Non-Neovascular

See more